首页> 外文期刊>Clinical Science >Sandhu, H., Maddock, H.Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury
【24h】

Sandhu, H., Maddock, H.Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury

机译:Sandhu,H.,Maddock,H.Mmoletular的癌症治疗诱导的心脏毒性:引入MicroRNA生物标志物,用于早期评估亚临床心肌损伤

获取原文
获取原文并翻译 | 示例
           

摘要

Development of reliable biomarkers for early clinical assessment of drug-induced cardiotoxicity could allow the detection of subclinical cardiac injury risk in vulnerable patients before irreversible damage occurs. Currently, it is difficult to predict who will develop drug-induced cardiotoxicity owing to lack of sensitivity and/or specificity of currently used diagnostics. miRNAs are mRNA regulators and they are currently being extensively profiled for use as biomarkers due to their specific tissue and disease expression signature profiles. Identification of cardiotoxicity-specific miRNA biomarkers could provide clinicians with a valuable tool to allow prognosis of patients at risk of cardiovascular injury, alteration of a treatment regime or the introduction of an adjunct therapy in order to increase the long-term survival rate of patients treated with cardiotoxic drugs.
机译:可靠的生物标志物用于早期临床评估药物诱导的心脏毒性,可能允许在不可逆损伤发生之前检测弱势患者的潜在患者心脏损伤风险。 目前,由于缺乏目前使用的诊断的敏感性和/或特异性,难以预测谁将患有药物诱导的心脏毒性。 MiRNA是MRNA监管机构,目前它们目前正在广泛地分析为生物标志物,因为它们的特定组织和疾病表达特征概况。 鉴定心脏毒性特异性miRNA生物标志物可以提供临床医生,具有有价值的工具,以允许在心血管损伤的风险下预后,改变治疗制度或引入辅助治疗,以提高治疗患者的长期存活率 用心脏毒性药物。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号